Infant Bacterial Therapeutics AB (publ) (IBT-B.ST)
SEK 50.3
(-2.52%)
SEK 50.3
(-2.52%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -123.06 Million SEK | -89.06% |
| 2022 | -65.09 Million SEK | -43.37% |
| 2021 | -45.4 Million SEK | 37.21% |
| 2020 | -72.31 Million SEK | -53.7% |
| 2019 | -47.04 Million SEK | -15.85% |
| 2018 | -40.6 Million SEK | -12.31% |
| 2017 | -36.15 Million SEK | 5.12% |
| 2016 | -38.1 Million SEK | -84.77% |
| 2015 | -20.62 Million SEK | -205.68% |
| 2014 | -6.74 Million SEK | 0.0% |
| 2013 | - SEK | 100.0% |
| 2012 | -1705.00 SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -42.67 Million SEK | -53.42% |
| 2024 Q1 | -27.81 Million SEK | 31.98% |
| 2023 Q2 | -28.82 Million SEK | -28.27% |
| 2023 FY | -123.06 Million SEK | -89.06% |
| 2023 Q4 | -40.89 Million SEK | -32.38% |
| 2023 Q3 | -30.88 Million SEK | -7.18% |
| 2023 Q1 | -22.46 Million SEK | 43.08% |
| 2022 Q2 | 1.64 Million SEK | 108.52% |
| 2022 Q4 | -39.47 Million SEK | -404.92% |
| 2022 FY | -65.09 Million SEK | -43.37% |
| 2022 Q1 | -19.33 Million SEK | -19.24% |
| 2022 Q3 | -7.81 Million SEK | -574.39% |
| 2021 Q4 | -16.21 Million SEK | -27862.07% |
| 2021 FY | -45.4 Million SEK | 37.21% |
| 2021 Q1 | 451 Thousand SEK | 101.69% |
| 2021 Q3 | -58 Thousand SEK | 99.8% |
| 2021 Q2 | -29.16 Million SEK | -6566.74% |
| 2020 Q1 | 1.17 Million SEK | 104.28% |
| 2020 Q3 | -18.6 Million SEK | 33.42% |
| 2020 Q4 | -26.64 Million SEK | -43.27% |
| 2020 FY | -72.31 Million SEK | -53.7% |
| 2020 Q2 | -27.93 Million SEK | -2471.56% |
| 2019 Q4 | -27.53 Million SEK | -161.28% |
| 2019 Q3 | -10.53 Million SEK | -39.37% |
| 2019 Q2 | -7.56 Million SEK | -1002.19% |
| 2019 FY | -47.04 Million SEK | -15.85% |
| 2019 Q1 | -686 Thousand SEK | 97.16% |
| 2018 Q3 | -7.98 Million SEK | -1300.75% |
| 2018 Q1 | -9.14 Million SEK | -0.94% |
| 2018 FY | -40.6 Million SEK | -12.31% |
| 2018 Q4 | -24.14 Million SEK | -202.35% |
| 2018 Q2 | 665 Thousand SEK | 107.27% |
| 2017 Q2 | -13.82 Million SEK | -61.47% |
| 2017 Q1 | -8.56 Million SEK | 39.29% |
| 2017 FY | -36.15 Million SEK | 5.12% |
| 2017 Q3 | -4.58 Million SEK | 66.83% |
| 2017 Q4 | -9.05 Million SEK | -97.54% |
| 2016 Q4 | -14.1 Million SEK | -82.78% |
| 2016 Q2 | -10.97 Million SEK | -112.49% |
| 2016 Q1 | -5.16 Million SEK | -206.97% |
| 2016 FY | -38.1 Million SEK | -84.77% |
| 2016 Q3 | -7.71 Million SEK | 29.69% |
| 2015 Q3 | 4.82 Million SEK | 199.76% |
| 2015 Q1 | -4.84 Million SEK | 0.0% |
| 2015 FY | -20.62 Million SEK | -205.68% |
| 2015 Q4 | 4.82 Million SEK | 0.0% |
| 2015 Q2 | -4.84 Million SEK | 0.0% |
| 2014 FY | -6.74 Million SEK | 0.0% |
| 2013 FY | - SEK | 100.0% |
| 2012 FY | -1705.00 SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alzinova AB (publ) | -16.48 Million SEK | -646.772% |
| Amniotics AB (publ) | -30.87 Million SEK | -298.665% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -859.37% |
| BioArctic AB (publ) | 229.24 Million SEK | 153.683% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 73.601% |
| Saniona AB (publ) | -95.81 Million SEK | -28.45% |
| Simris Alg AB (publ) | -37.3 Million SEK | -229.897% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 60.421% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -483.51% |
| NextCell Pharma AB | -41.95 Million SEK | -193.3% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -650.507% |
| AcouSort AB (publ) | -17.08 Million SEK | -620.159% |
| Active Biotech AB (publ) | -45.8 Million SEK | -168.707% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 50.493% |
| Camurus AB (publ) | 431.44 Million SEK | 128.525% |
| Cantargia AB (publ) | -280.02 Million SEK | 56.051% |
| Genovis AB (publ.) | 61.5 Million SEK | 300.111% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | -8.599% |
| Mendus AB (publ) | -101.61 Million SEK | -21.107% |
| Kancera AB (publ) | -64.88 Million SEK | -89.659% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 2384.961% |
| LIDDS AB (publ) | -40.2 Million SEK | -206.094% |
| Lipum AB (publ) | -37.17 Million SEK | -231.024% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -914.743% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 1111.324% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -587.646% |
| OncoZenge AB (publ) | -15.9 Million SEK | -673.915% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 68.295% |
| Xintela AB (publ) | -54.08 Million SEK | -127.554% |
| Ziccum AB (publ) | -21.41 Million SEK | -474.762% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -231.979% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 31.502% |
| CombiGene AB (publ) | -35.66 Million SEK | -245.063% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 18.954% |
| Intervacc AB (publ) | -102.85 Million SEK | -19.655% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -27997.717% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -644.828% |
| Corline Biomedical AB | -1.8 Million SEK | -6703.096% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 30.798% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | -116.589% |
| Aptahem AB (publ) | -11.11 Million SEK | -1007.437% |
| Fluicell AB (publ) | -26.55 Million SEK | -363.463% |
| Biovica International AB (publ) | -124.82 Million SEK | 1.406% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -191.471% |
| Abliva AB (publ) | -95.5 Million SEK | -28.855% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 62.353% |
| 2cureX AB (publ) | -32.51 Million SEK | -278.461% |
| I-Tech AB | 20.2 Million SEK | 709.157% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 85.203% |
| Cyxone AB (publ) | -22.98 Million SEK | -435.334% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | -34.646% |
| Biosergen AB | -27.03 Million SEK | -355.184% |
| Nanologica AB (publ) | -75.15 Million SEK | -63.748% |
| SynAct Pharma AB | -215.81 Million SEK | 42.974% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | -179.357% |
| BioInvent International AB (publ) | -330.3 Million SEK | 62.741% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -418.465% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 50.597% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -1139.354% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | -12.609% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -953.845% |